Evidence map›Paper›PMID 42358640›Full record

ArticleFrontiers in cardiovascular medicine2026

Evolution of advanced revascularization strategies for high-risk pulmonary embolism: a physiology-guided single-center experience.

L W Greenspon, S Whealon, J Bonn, M Caroline, E Gnall

Abstract read
In one paragraph

Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

L W GreensponPulmonary and Critical Care, Lankenau Medical Center, Wynnewood, PA, United States.
S WhealonPulmonary and Critical Care, Lankenau Medical Center, Wynnewood, PA, United States.
J BonnInterventional Radiology, Lankenau Medical Center, Wynnewood, PA, United States.
M CarolineInterventional Cardiology, Lankenau Medical Center, Wynnewood, PA, United States.
E GnallInterventional Cardiology, Lankenau Medical Center, Wynnewood, PA, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Management of pulmonary embolism (PE) has evolved substantially over the past several decades, yet optimal integration of emerging therapies remains challenging. This Perspective describes our 4 decade, single-center experience reflecting the transition from systemic thrombolysis to catheter-directed therapies (CDT) and, more recently, large bore mechanical thrombectomy supported by interventional cardiology with ECMO back-up. Our approach has increasingly focused on physiologic assessment including right ventricular function, pulmonary artery pressures, and cardiac output in the face of the patient's age, underlying cardiopulmonary disease and presence of proximal deep vein thrombosis. This evolution has been characterized by progressive adoption of CDT, reassessment, and refinement of therapies in response to both clinical experience, emerging evidence and participation in clinical trials. The development of a pulmonary embolism response team (PERT) and more recently integration of artificial intelligence detection systems have further improved early recognition of intermediate and high-risk PE cases and coordination of care. Our experience over four decades highlights key lessons and the importance of early physiologic recognition of severity, selective use of reperfusion therapies, and the critical role of a dedicated multidisciplinary system of care.

Indexed as

catheter directed therapy (CDT)mechanical thrombectomypulmonary embolismpulmonary embolism response team (PERT)thrombolysis

Identifiers

PMID42358640
PMCPMC13290958

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.